Current and emerging therapies in metastatic pancreatic cancer

Gulam Abbas Manji, Kenneth P. Olive, Yvonne M. Saenger, Paul Oberstein

Research output: Contribution to journalArticlepeer-review

103 Scopus citations


Targeted therapies and immunotherapy have changed the face of multiple solid malignancies, including metastatic melanoma and lung cancer, but no such therapies exist for pancreatic ductal adenocarcinoma (PDAC) despite the knowledge of key mutations and an increasing understanding of the tumor microenvironment. Until now, most clinical studies have not been biomarker driven in this highly immunosuppressive and heterogeneous cancer. Ongoing basic and translational studies are better classifying the disease inhopes of identifying critical pathways that distinguish the unique PDAC subtypes, which will lead to personalized therapies. In this review, we discuss the current treatment options for metastatic pancreatic cancer and highlight current ongoing clinical trials, which aimto target the stroma and the immunemicroenvironment either alone or in combination with standard chemotherapy. Identifying biomarkers and key resistance pathways and targeting these pathways in a personalized manner in combination with chemotherapy are likely to yield a more immediate and durable clinical benefit.

Original languageEnglish (US)
Pages (from-to)1670-1678
Number of pages9
JournalClinical Cancer Research
Issue number7
StatePublished - Apr 1 2017
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Current and emerging therapies in metastatic pancreatic cancer'. Together they form a unique fingerprint.

Cite this